NCP

NEACH Announces Recipients of the 2024 Excellence Awards

Retrieved on: 
月曜日, 5月 20, 2024
Professional Services, Payments, Technology, Finance, Fintech, Banking, NCP, Organization, API, Digital, Credit union, ACH, Heart, Braid, RDC, Savings bank, Human, Eye, AAP

Today, the New England Automated Clearing House (NEACH) announced the winners of its NEACH Excellence Awards, which showcase outstanding payments contributions in leadership, products, or services to the financial services industry.

Key Points: 
  • Today, the New England Automated Clearing House (NEACH) announced the winners of its NEACH Excellence Awards, which showcase outstanding payments contributions in leadership, products, or services to the financial services industry.
  • As members of NEACH, award recipients display critical characteristics that support the transformation of payments through innovation, dedication, and excellence.
  • “The NEACH Excellence Awards are designed to recognize the hard work of the financial institutions and businesses in New England and throughout the U.S.,” said Sean Carter, AAP, APRP, NCP, President and CEO, NEACH.
  • In addition, NEACH supports industry growth and development through NEACH U, its educational institution; monthly educational opportunities like webinars; accreditation programs; and much more.

OKYO Pharma Announces Participation in May 2024 Investor Conferences

Retrieved on: 
水曜日, 5月 8, 2024
FDA, Pain, DED, NCP

LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.

Key Points: 
  • LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.

High Noon Levels Up the RTD Category with the Release of High Noon Vodka Iced Tea

Retrieved on: 
月曜日, 5月 6, 2024
Vol, MSRP, IRI, Originality, High Noon, Tea, RTD, NCP, ABV, Gallo

MODESTO, Calif., May 6, 2024 /PRNewswire/ -- Spirit of Gallo's High Noon, the #1 spirits brand by volume**, is launching High Noon Vodka Iced Tea, made with real vodka, real iced tea, and no added sugar. Now available on shelves nationwide, High Noon's new non-carbonated, gluten free hard teas are available in four essential summer flavors – Original, Peach, Lemon, and Raspberry – each at 90 calories and 4.5% ABV with an MSRP of $19.99 in 8-packs of 355mml cans.

Key Points: 
  • MODESTO, Calif., May 6, 2024 /PRNewswire/ -- Spirit of Gallo's High Noon , the #1 spirits brand by volume**, is launching High Noon Vodka Iced Tea, made with real vodka, real iced tea, and no added sugar.
  • High Noon Vodka Iced Tea is the ideal companion for backyard barbecues, beach days, and any occasion where good times are on the menu.
  • High Noon Vodka Iced Tea joins a growing High Noon family alongside consumer favorites like High Noon Vodka Seltzer and High Noon Tequila Seltzer.
  • For more information on High Noon and the new line of Vodka Iced Tea, visit HighNoonSpirits.com or check them out on Instagram .

Northlane Capital Partners Announces the Sale of VMG Health

Retrieved on: 
木曜日, 4月 18, 2024
Professional Services, Health, Other Professional Services, Finance, General Health, Banking, Sale, Hospital, Partnership, History, NCP, VMG, Growth

Northlane Capital Partners (“NCP”) announced today the sale of its equity interest in VMG Health (the “Company’) to Incline Equity Partners.

Key Points: 
  • Northlane Capital Partners (“NCP”) announced today the sale of its equity interest in VMG Health (the “Company’) to Incline Equity Partners.
  • VMG Health provides a unique combination of healthcare industry, financial, and operational expertise to its customers nationwide.
  • VMG Health has solidified its position as a leading healthcare advisory firm, offering indispensable solutions to its clients.”
    Greg Koonsman, Founder & CEO of VMG Health, commented “The sale of VMG Health marks a significant milestone in our history.
  • The sale of VMG Health represents another compelling example of our success in investing in niche market leaders that deliver essential outsourced services to their customers.”

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Retrieved on: 
火曜日, 4月 9, 2024
Research, NCP, KOL, ARVO, DED, Pain, FDA

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.

Key Points: 
  • LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.
  • The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences.
  • OKYO is planning to make a presentation at “Dry Horizons Symposium Navigating the Future of Dry Eye Research”, an event preceding the Association for Research in Vision and Ophthalmology (ARVO) conference with details provided below.

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Retrieved on: 
火曜日, 4月 2, 2024
NCP, Refractive surgery, ASCRS, Cataract, DED, Society, Pain, Telecanthus, FDA, Annual general meeting

LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

Key Points: 
  • LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Retrieved on: 
金曜日, 3月 22, 2024
Day, Ora, Dry, NCP, Conjunctiva, BID, Physiology, Patient, Pain, Ophthalmology, Observation, Blurred Vision, Doctor of Philosophy, Itch, DED, MOA, Safety, Screen time, Telecanthus, Medical director, FDA, Pharmaceutical industry

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.

Key Points: 
  • Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.
  • Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder of the trial.
  • Burning/Stinging, and Blurred Vision improved as early as day 15 and the benefit remained durable throughout the trial.
  • Significant improvements were observed across multiple symptoms as measured in a daily symptom diary including pain, burning/stinging, eye dryness and itching within the first two weeks of treatment.

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Retrieved on: 
木曜日, 3月 21, 2024
Visual Science, Uveitis, Wilmer Ophthalmological Institute, Brandeis University, Neurophysiology, NCP, BID, Telecanthus, Research, KOL, University, Patient, Doctor of Philosophy, Bascom Palmer Eye Institute, DED, Georgetown University Medical Center, Pain, Therapy, Johns Hopkins Hospital, Medical director, FDA, Pharmaceutical industry

LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024.

Key Points: 
  • OKYO Pharma’s management team will also be in attendance to present an overview of OK-101’s mechanism of action.
  • He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Retrieved on: 
水曜日, 3月 20, 2024
NCP, BID, Patient, KOL, IND, DED, Safety, Pain, Telecanthus, FDA, Health, Pharmaceutical industry

The company will also host a Key Opinion Leader (KOL) event to discuss the findings in depth.

Key Points: 
  • The company will also host a Key Opinion Leader (KOL) event to discuss the findings in depth.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The KOL call will feature prominent experts in the field of dry eye disease.
  • “The upcoming data release follows the successful completion of OKYO Pharma's Phase 2 trial, which focused on assessing the efficacy and safety of OK-101, our novel topical therapeutic candidate for dry eye disease,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma.

Paysign, Inc. Reinforces Payment Processing Acumen With New Executive Hire

Retrieved on: 
水曜日, 3月 13, 2024
Technology, Human Resources, Payments, Finance, Security, Fintech, Banking, Professional Services, Data Management, Organization, Risk management, NCP, ACH, NACHA, National Check Professional, Operation, AAP, Multimedia, EFT, Cryptocurrency

Paysign, Inc. (NASDAQ: PAYS ), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced a key executive recruitment that supports their foundation as an end-to-end payment processor.

Key Points: 
  • Paysign, Inc. (NASDAQ: PAYS ), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced a key executive recruitment that supports their foundation as an end-to-end payment processor.
  • Sandy Ortins, AAP, APRP, NCP, was brought on as the company’s vice president of electronic funds transfer (EFT) services, an essential addition to the team.
  • She holds three professional credentials that highlight her commitment to payment processing: Accredited ACH Professional (AAP), Accredited Payments Risk Professional (APRP) and National Check Professional (NCP).
  • As Paysign’s VP, EFT Services, Sandy will focus on day-to-day processing operations, including audit, compliance, risk management, and future processing connections.